coagulopathy in cardiac surgery1
Post on 07-Apr-2018
225 Views
Preview:
TRANSCRIPT
-
8/4/2019 Coagulopathy in Cardiac Surgery1
1/63
COAGULOPATHY IN
CARDIAC SURGERYBY:Dr Hatem Mohd Altaher
-
8/4/2019 Coagulopathy in Cardiac Surgery1
2/63
Coagulation and bleeding assume particular importance whenoperations are performed on the heart using extracorporeal
circulation.
The interaction of the platelets, endothelial cells, andproteins to either activate or deactivate coagulation is ahighly buffered and controlled process.
Coagulation itself the injury/controlleading to hemostasis isa four-part event
acceleration
controllysis
initiation
-
8/4/2019 Coagulopathy in Cardiac Surgery1
3/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
4/63
Platelet activation by CPB
Activation
-
8/4/2019 Coagulopathy in Cardiac Surgery1
5/63
CPB negativelychargedplastic surface
-
8/4/2019 Coagulopathy in Cardiac Surgery1
6/63
The central role of Thrombin (Thr) inhemostatic activation
-
8/4/2019 Coagulopathy in Cardiac Surgery1
7/63
Modulating effects of coagulation.
ATIII
thrombin
Thrombin + ATIII
II ,XIIa,XIa, and Xa;kallikrein;plasmin.
Heparan&
heparin
VIIa & Xa
heparin
TFPI+
-
8/4/2019 Coagulopathy in Cardiac Surgery1
8/63
The fibrinolytic system
-
8/4/2019 Coagulopathy in Cardiac Surgery1
9/63
BLEEDING PATIENT
Following cardiac surgery, some patients bleed excessively.Prompt diagnostic and therapeutic action will avoidimpaired hemodynamics, decreased oxygen-carryingcapacity, and impaired hemostasis from depletion ofendogenous hemostatic resources.
creates the potential for hemorrhage, sometimes aided bypreoperative attempts to lyse intracoronary thromboses.Beyond that, however, many factors govern whether aparticular patient will experience excessive bleeding aftercardiac surgery.
Excessive bleeding,a chest tube drainage > 10 mLlkg in the first hour post op
or a total of > 20 mLlkg over the first 3 hourspost opany sudden increase of >300 mLlhr or greater following
minimal initial drainage
-
8/4/2019 Coagulopathy in Cardiac Surgery1
10/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
11/63
I- Patient Factorspatient with a personal or family history of abnormal bleedingfollowing surgery should be investigated.
Concurrent systemic disease affects hemostasis duringsurgery.
Uremia from RF results in platelet dysfunction.
Severe hepatic compromise impairs every aspect of hemostasis:prekallikrein and most coagulation factors
splenomegaly induces thrombocytopenia; maldistribution ofvWF lead to impairs platelet adhesiveness and aggregation;
impaired clearance of endogenous plasminogen activatorsaccentuates fibrinolysis; and decreased levels of coagulationinhibitors induce a consumptive coagulopathy.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
12/63
II- Medications
warfarin hold 2 to 5 days.urgent surgery parenteral vitamin K or FFP
thrombolytic therapy as streptokinase should respond toantifibrinolytic therapy with (EACA) or tranexamic acid.
ASA or other platelet-inhibiting drugs regularly cannot haltthat therapy within 7 days of surgery. No antidote can correct
the platelet defect.
B-Lactam antibiotics coat the platelet membrane, while thecephalosporins are rather profound but short-term plateletinhibitors. Many cardiac surgeons may not realize that theirstandard drug regimen for antibiotics may be far more of ableeding risk than aspirin
-
8/4/2019 Coagulopathy in Cardiac Surgery1
13/63
Half-life
RouteIndicationsMechanismCompositionDrug Type
10-
days
OralCAD, AMI,
PVD, PCI,ACS
Irreversible COX
inhibition
Acetylsalicylic
acid
Aspirin
2days
OralPainReversible COXinhibition
MultipleNSAIDs
12 hrOralVHD, PVDReversible COX
inhibition
MultipleAdhesion inhibitors
(e.g., dipyridamole)5days
OralAMI, CVA,PVD, ACS,PCI
Irreversibleinhibition of ADPbinding
ThienopyridinesADP receptorantagonists
(e.g., clopidogrel)
GPllb/llla receptorinhibitors
12 to18 hr
IVPCI, ACSNonspecific-bindsto other receptors
Monoclonalantibody
Abciximab (ReoPro)
2 to 4hr
IVPCI, ACSReversible-specific toGPllb/llla
PeptideEptifibatide (Integrilin)
2 to 4hr
IVPCI, ACSReversible -specific to
Nonpeptide-t rosine
TIrofiban (Aggrastat)
II- Anti-platelet
-
8/4/2019 Coagulopathy in Cardiac Surgery1
14/63
III- Insult of CPB
A-FibrinolysisNumerous investigations support the notion that CPB activates thefibrinolytic pathway.
Why might this occur?Despite clinically adequate doses and blood concentrations of heparin,coagulation pathway activity persists. Formation of prothrombin and
fibrinopeptide fragments and thrombin-antithrombin complexescontinued.
The site of thrombin activity probably resides in the ECC , whichcontains a large surface of thrombogenic material. Thrombinactivation results in fibrinolytic activity. Activation of fibrinolysis
Plasminogen activator concentrations rise during CPB, while levels ofits inhibitor PAl-I remain unchanged.
Does fibrin formation during CPB constitute a consumptivecoagulopathy?
-
8/4/2019 Coagulopathy in Cardiac Surgery1
15/63
B-Thrombocytopenia
Thrombocytopenia occurs during CPB as a result of
Hemodilution. Heparin.
hypothermia-induced. splenic sequestration of platelets.
platelet destruction from the blood-gas and blood-tissueinterfaces created by cardiotomy suction, filters, and bubbleoxygenators.
Platelet count rarely drops below 50,000/mm3.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
16/63
C- platelet dysfunction
Not only does the number of platelets decrease during CPB, but
remaining platelets become impaired by partial activation.
Fibrinogen and fibrin, which adhere to artificial surfaces of the ECC,form a nidus for platelet adhesion and aggregation. reducedcontent of platelet granules constitutes the evidence for partialactivation.
Nearly one-third of circulating platelets undergo a-granular releaseduring CPB.
also depletes platelet glycoprotein receptors Ib and IIb/I1Ia.Use of frequent cardiotomy suction and bubble oxygenators
aggravates the extent of platelet activation.
Activation of the fibrinolytic system may contribute to plateletdysfunction.
Antifibrinolytic medications preserve platelet function and preventsome platelet abnormalities that occur during bypass
-
8/4/2019 Coagulopathy in Cardiac Surgery1
17/63
D-Clotting Factors
Denaturation of plasma proteins, including the coagulationfactors, occurs at blood-air interfaces. Liberal use ofcardiotomy suction and prolonged use of bubbleoxygenators potentially impair coagulation by decreasingcoagulation.
Hemodilution also decreases factor concentrations.
However, rarely do coagulation factor levels fall below thethresholds for adequate formation of fibrin in adult surgery.
In infants, however, the smallest achievable pump primingvolumes can dilute factors to below 30% of normal levels.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
18/63
IV-Hypothermia
First, the splanchnic circulation responds to hypothermia withsequestration of platelets.
Second, transient platelet dysfunction occurs, evidenced by aplatelet shape change, increased adhesiveness, inhibition ofADP-induced aggregation, and decreased synthesis of boththromboxane and prostacyclin.
Third, hypothermia slows the enzymatic cleavage upon whichactivation of coagulation factors depends.
Many biologic phenomena display a 7% attenuation of activity
for each decrease of 1C in temperature. While coagulationfactor structure remains unaltered, formation of fibrin may besluggish when the patient is cold.
Fourth, hypothermia accentuates fibrinolysis.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
19/63
Prevention of BleedingA-Preoperative Factors
Identified and treated existing disorders of hemostasis.
The bleeding diathesis of uremia responds to hemodialysis, redblood cell transfusion, and administration of desmopressin.
Impaired hemostasis from hepatic failure may respond tointravenous desmopressin.
Correction of hematologic disordersAdministration of platelet-inhibiting drugs should cease pre OR
Aspirin 10 days NSAIDs 2 days ADP receptor antagonists (e.g., c1opidogrel)5 days GPllbllla receptor inhibitors Tirofiban (Aggrastat) 2 to 4hr
P ti f Bl di
-
8/4/2019 Coagulopathy in Cardiac Surgery1
20/63
Prevention of Bleeding
B-Physical Factors
Correction of Hypothermia
Incomplete surgical hemostasis
Limiting the intensity and frequency of use of thecardiotomy suction Selection.
membrane Vs bubble-type oxygenator
Centrifuge Vs Roller pump
A small priming volum.ANH
-
8/4/2019 Coagulopathy in Cardiac Surgery1
21/63
B-Physical Factorscont.- Speed of surgery Shorter CPB duration
Preserves platelet function and limits the coagulant stimulus for subsequent fibrinolysis. limits tissue exposure to the hypothermia
positive END-EXPIRATORY PRESSURE(5 to 10cm H20).
A tamponade effect in the mediastinum may explain thissalutary effect.
Unfortunately, controlled studies have not confirmed thisbenefit. Also, excessive pressure impedes venous return,
worsening hemodynamics in the hypoovolemic patient.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
22/63
B-Physical Factorscont
- maiaintenance of systemic blood pressure inthe low-normal range promotes tissue perfusionwhile limiting leakage around suture lines.
Adequate depth of anesthesia during surgery andsufficient postoperative analgesia and sedationshould be verified prior to initiating vasodilatortherapy.
Topical haemostatic agents Fibrin sealants arecomposed of human fibrinogen, human or bovinethrombin or human factor VIII and bovineaprotinin.
C
-
8/4/2019 Coagulopathy in Cardiac Surgery1
23/63
C-blood ProductsThe bleeding patient becomes subject to additional hemostatic
derangements. The need to maintain intravascular blood volume
arises in nearly all cases prior to identification of the cause ofbleeding.
However, red blood cells,platelets, and coagulation factorsbecome diluted when continued bleeding is treated with suchreplacement. Also, PRBCs and banked whole blood do not
provide platelets or sufficient factor V & VIII to maintainhemostasis.
Although routine prophylactic administration of FFP or plateletsplays no role in modern cardiac surgical care.
A platelet counr below 100,000/mm3 or prolongation of the PTor aPTT despite adequate heparin neutralization in a patientactively bleeding is an indication for platelet or plasmareplacement in the absence of coagulation tests toguide therapy
-
8/4/2019 Coagulopathy in Cardiac Surgery1
24/63
D-Pharmacological Intervention
HEPARIN AND PROTAMINE
Too little heparin invites active fibrin formation during CPB withconsumption of clotting factors and platelets and excessiveactivation of the fibrinolytic system.
Too much heparin risks postoperative heparin rebound.
With too little protamine, the remaining unneutralized heparinimpairs hemostasis by its anticoagulant action.
Doses of protamine excessive enough to overwhelm theendogenous proteases may exert an anticoagulant effect, aswell as induced lung injury and pulmonary vasoconstriction.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
25/63
HEPARIN AND PROTAMINE
ACT nearly doubling following a protamine dosefour times
that needed to neutralize heparin.
At a lO-fold dose, the ACT prolonged andthrombocytopenia developed
The optimal approach utilizes coagulation testingto estimate the appropriate heparin and
protamine doses, and confirm both adequateanticoagulation and its neutralization.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
26/63
D-Pharmacological Interventioncont.
DESMOPRESSIN
This analog of vasopressin desmopressin releases coagulationsystem mediators from vascular endothelium.
Factor VIII increases 2- to 20-fold.
Factor XII levels Endothelium : releases of vWF.
Specific applications of desmopressin's hemostatic benefitinclude :
uremia, Correction of prolonged bleeding times
Liver cirrhosis patientsshortens prolonged bleeding times.
corrected the aspirin-induced prolongation in bleeding time
-
8/4/2019 Coagulopathy in Cardiac Surgery1
27/63
D-Pharmacological Interventioncont.SYNTHETIC ANTIFIBRINOlYTICS
For decades, antifibrinolytics have been proposed as potentialhemostatic agents during cardiac surgery.
Prophylactic antifibrinolytics may spare platelet function byinhibiting the deleterious effects of plasmin.
These simple molecules analogs of the amino acid lysine, bindto plasminogen and plasmin, thus inhibiting binding ofplasminogen at the lysine residues of fibrinogen.
Antifibrinolytics undergo renal concentration and excretion witha plasma half-life of about 80 minutes.
The loading dose of 10mg/kgfor TA followed by 1mg/kg/hror 50 mg/kg of EACAthen 25 mg/kg/hr
-
8/4/2019 Coagulopathy in Cardiac Surgery1
28/63
Pharmacokinetic studies demonstrate a need to readministera bolus of EACA upon institution of CPB.
Several investigations, using prophylactic antifibrinolytics;document a savings in blood loss, as well as in bloodtransfused in a general population of cardiac surgery
chest tube drainage in the first 12 hours following operationdecreased by 30%,
The likelihood of receiving banked blood within 5 days ofoperation decreased from 41% to 22%:48
Administration of very largedoses of antifibrinolytics appearsto offer no greater savings.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
29/63
Recombinant Factor Seven
Factor VII is synthesized in the liver has the shortest half-life ofall procoagulant factors (3-6 h).
Novel indications for rFVIIa (based on case reports & clinicaltrials)
Patients with liver disease,
Thrombocytopenia, or Qualitative platelet dysfunction
Patients with no coagulation disorders who are bleeding as aresult of extensive surgery or major trauma
D-Pharmacological Interventioncont.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
30/63
Activated recombinant factor VII aftercardiopulmonary bypass
reduces allogeneic transfusion in complexnon-coronary
cardiac surgery: randomized double-blindplacebo-controlled pilot study
British Journal of Anaesthesia
95 (5): 596602 (2005)
-
8/4/2019 Coagulopathy in Cardiac Surgery1
31/63
2006Effective Management of Refractory Postcardiotomy
Bleeding With the Use of Recombinant ActivatedFactor VII
Farzan Filsoufi, MD, Javier G. Castillo, MD, Parwis B.Rahmanian, MD,Corey Scurlock, MD, Gregory Fischer, MD,
and David H. Adams, MDDepartments of Cardiothoracic Surgery and Anesthesiology,
Mount Sinai Hospital, New York, New York
-
8/4/2019 Coagulopathy in Cardiac Surgery1
32/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
33/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
34/63
Crit. Care Med. 2005;
33(10)Von HeymannC ;et al, Department of
Anesthesiology and Intensive Care
Medicine, St. Mary's Medical Center,San Francisco, CA, USA
-
8/4/2019 Coagulopathy in Cardiac Surgery1
35/63
STUDIESBlood loss and transfusion requirementswere significantly reduced in the periodafter the administration of rFVIIa.
Early Mortality and 6-month survival rates
were not different between the groups.
No thromboembolic complications wereobserved in the rFVIIa group
CONCLUSIONS: When used as a lastresort, rFVIIa was safe , efficacious overconventional hemostatic therapy
n=24
-
8/4/2019 Coagulopathy in Cardiac Surgery1
36/63
2007
Recombinant Activated Factor VII inCardiacSurgery: A Systematic Review
Oliver Warren, MRCS, et al, Department of
BioSurgery and Surgical Technology, St.Marys Hospital, London, UK
-
8/4/2019 Coagulopathy in Cardiac Surgery1
37/63
Journal ofCardiothoracic and
Vascular Anesthesia,Recombinant Activated Factor VII in Cardiac Surgery: A Meta-
analysis
2009performed a meta-analysis of 5 clinical trials
hemostatic properties of rFVIIa could reduce the rate of surgicalreexploration after cardiac surgery even if an increase of hazardous side
effects (eg, perioperative stroke) could not be excluded.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
38/63
Pediat. Crit Care Med. 2005
WittensteinB ;NgC ;RavnH;GoldmanA
Great Ormond Street Hospital forChildren, London, UK
Th b b li d f d f
-
8/4/2019 Coagulopathy in Cardiac Surgery1
39/63
Thromboembolic adverse events after used offactor VIIa
OConnell K JAMA 2006: 295:293
-
8/4/2019 Coagulopathy in Cardiac Surgery1
40/63
Retrospective review of factor VII use in 18Canadian centres, 2003 2006
Data collected on 503 patients
-
8/4/2019 Coagulopathy in Cardiac Surgery1
41/63
Blood Coag Fibrinolysis 2006;17:389
Factor VIIa in cardiac surgery: a systematic
-
8/4/2019 Coagulopathy in Cardiac Surgery1
42/63
Factor VIIa in cardiac surgery: a systematicreview
Warren O Ann Thorac Surg 2007; 83:707
-
8/4/2019 Coagulopathy in Cardiac Surgery1
43/63
Thromboembolic adverse events after used of
-
8/4/2019 Coagulopathy in Cardiac Surgery1
44/63
Thromboembolic adverse events after used offactor VIIa
OConnell K JAMA 2006: 295:293
431 AE reports
168 patients had thrombotic events
-
8/4/2019 Coagulopathy in Cardiac Surgery1
45/63
WHAT TO DO
-
8/4/2019 Coagulopathy in Cardiac Surgery1
46/63
Coagulation monitoring
Test
PlateletsPlatelet count 150,000-400,0001IlLBleeding time
-
8/4/2019 Coagulopathy in Cardiac Surgery1
47/63
Coagulation monitoring
-
8/4/2019 Coagulopathy in Cardiac Surgery1
48/63
Coagulation monitoring
ADP Test
No oozing at puncture sites;
-
8/4/2019 Coagulopathy in Cardiac Surgery1
49/63
Desmopressin O.3uglkgIV
Aminocaproic acid or
Tranexamic acid
Fibrinogen 1.5 timescontrol
Platelet count 150 sec or aPTT >1.5
times control
Core" temperature
-
8/4/2019 Coagulopathy in Cardiac Surgery1
50/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
51/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
52/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
53/63
-
8/4/2019 Coagulopathy in Cardiac Surgery1
54/63
There have been fewer randomized trials of tranexamicacid or aminocaproic acid. One trial [15] of 210 cardiacsurgery patients randomized to receive tranexamic acid orplacebo resulted in a significant reduction in the proportionof patients requiring any blood product in thetranexamic group (12.5%) compared with the placebogroup (31.1%).A Cochrane review [8] of over 200 clinical trials (notlimited to cardiac surgery) found that antifibrinolyticdrugs used at the time of major surgery reduced bleeding,the need for transfusion and the need for repeat surgerybecause of bleeding. The authors [8] found that lysineanalogues were probably as effective as aprotinin and
were cheaper; the evidence for tranexamic acid is strongerthan for aminocaproic acid. Large variations indosages used between the published studies make itimpossible to evaluate the relationship between dosageand efficacy.In the paediatric population, antifibrinolytics have beenused for scoliosis surgery. A Cochrane review [16] showed
that antifibrinolytics reduce blood loss, but their effect on
-
8/4/2019 Coagulopathy in Cardiac Surgery1
55/63
rFVIIa binds to tissue factor at the site of tissue injury andvascular wall disruption, generating thrombin and activatingplatelets. The activated platelet surface thenforms a template, on which rFVIIa mediates furtheractivation of coagulation. This in turn generates a thrombin
burst, which leads to the conversion of fibrinogen tofibrin. Furthermore, rFVIIa-mediated activation ofthrombin-activatable fibrinolysis inhibitor results in clotstabilization by inhibition of fibrinolysis [1].
-
8/4/2019 Coagulopathy in Cardiac Surgery1
56/63
Recombinant FVIIa is an expensive therapy; a singleadult dose of 90mgkg1 costs approximately 6000 Euros.Its use is difficult to justify on economic grounds alone,given the cost of one unit of red blood cells (175 Euros).There is evidence that the clinical efficacy varies at
different doses; in a meta-analysis, a subgroup analysisdetermined that at least 50mgkg1 was required for asignificant benefit [18]. Therefore, the role of this drughas yet to be established, and further research is required.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
57/63
Topical haemostatic agentsFibrin sealants are composed of human fibrinogen,human or bovine thrombin or human factor VIII andbovine aprotinin. They are topically applied and are usedquite commonly in cardiothoracic, vascular, liver and
spleen surgery to aid haemostasis at sites of cannulation,laceration and along suture lines [1]. A systematic review[26] of the use of fibrin sealants to minimize perioperativeallogeneic blood transfusion suggested that they areefficacious,although large methodologically rigorous trials arestill needed. In addition, such sealants are very expensive,and costbenefit analysis has yet to be performed, despiteaggressive marketing from the manufacturers.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
58/63
Autologous blood transfusionThere are three types of autologous blood transfusion:preoperative blood donation, acute normovolaemic haemodilution(ANH) and red blood cell salvage (intraoperativeand postoperative) [27]. A systematic review [28] ofrandomized controlled trials found that all three autologous
transfusion techniques consistently reduced the frequencyof allogeneic transfusions; the greatest relative riskreduction occurring with preoperative blood donation
Carless PA, Moxey A, OConnell D, Henry D. Autologoustransfusion
techniques: a systematic review of their efficacy. Transfus Med2004;14:123144.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
59/63
Acute normovolaemic haemodilutionANH is an autologous blood collection technique thatinvolves the removal of whole blood from the patientimmediately before surgery, along with simultaneousreplacement with an intravenous fluid (crystalloid or
colloid) in order to maintain normovolaemia. The bloodis collected in standard blood bags containing citrateanticoagulant; it remains in the operating room and isreinfused at an appropriate time during surgery, or at theend of surgery, usually after major blood loss has ceased.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
60/63
The efficacy of ANH in reducing allogeneic transfusion isdubious. Several prospective randomized trials [4043]have demonstrated that ANH reduces allogeneic bloodtransfusions in patients undergoing elective total kneereplacement, liver resection and cardiac surgery; however,
others [44,45] have failed to document any benefit.A meta-analysis of 42 trials [46] comparing ANH withalternative blood conservation methods or usual caresuggested that the efficacy of ANH was likely to besmall. It appears to modestly reduce bleeding and the
volume of allogeneic blood required, but its efficacy withregard to avoidance of allogeneic transfusion is unproven.
-
8/4/2019 Coagulopathy in Cardiac Surgery1
61/63
Red blood cell salvageRed blood cell salvage has become popular over the past10 years and is now used extensively in the surgicalsetting. Cell salvage is a term that covers a range oftechniques that scavenge blood from operative fields or
wound sites and reinfuse the blood back into the patient.Cell salvage can be performed during intraoperative orpostoperative periods or during both. To remove noncellularmatter prior to reinfusion, some of the devices usecentrifugal washing of the salvaged blood [48], whereas
others use a countercurrent system similar tohaemofiltration[49]. The processing of blood, however, necessarily
-
8/4/2019 Coagulopathy in Cardiac Surgery1
62/63
removes platelets and plasma proteins, which maycontributeto a dilutional coagulopathy. The washing processcan also lead to haemolysis, especially if suction pressuresare not carefully regulated or the washing process is
accelerated. In addition, retained plateletleukocytedeposits may produce procoagulant leukotactic substances,increasing the risk of disseminated intravascularcoagulation [50]. Relative contraindications include thepotential for aspiration of malignant cells, the presence ofinfection, gross bacterial contamination of the surgical field
and the presence of other contaminants such as amnioticfluid [51].
The effect of acute autologous blood transfusion on
-
8/4/2019 Coagulopathy in Cardiac Surgery1
63/63
The effect of acute autologous blood transfusion oncoagulation dysfunction after cardiopulmonary bypassAnaesthesiol 26:868873 Q 2009 European Society of
Anaesthesiology.
electivecardiac surgery with cardiopulmonary bypass. The patientsin group A underwent acute autologous blood transfusionwith acute normovolemic haemodilution and those in groupH received homologous blood, if needed, and served ascontrols.
Autologous blood transfusion of 15%estimated blood volume did not affect postcardiopulmonarybypass coagulopathy, nor did it decrease blood loss orhomologous blood and its products transfusion in the earlypostoperative period. TEG is a valuable measure fordetecting coagulation dysfunction with a potential role in thepostoperative management of cardiac patients
top related